We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$45.1M
1-Year Est. Return
74.25%
This Fund
S&P 500
This Quarter
Est. Return
-26.25%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$455M
AUM Growth
-$327M
(-42%)
Cap. Flow
-$168M
Cap. Flow
% of AUM
-36.97%
Top 10 Holdings %
Top 10 Hldgs %
79.01%
Holding
161
New
35
Increased
35
Reduced
40
Closed
40
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$28.9M |
| 2 |
State Street SPDR S&P Biotech ETF
XBI
|
+$5.02M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$1.86M |
| 4 |
RSLS
ReShape Lifesciences Inc. Common Stock
RSLS
|
+$1.72M |
| 5 |
ReWalk Robotics
LFWD
|
+$1.65M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Nektar Therapeutics
NKTR
|
+$8.71M |
| 2 |
Xeris Biopharma Holdings
XERS
|
+$5.7M |
| 3 |
FOLD
Amicus Therapeutics
FOLD
|
+$1.87M |
| 4 |
APTX
Aptinyx Inc. Common Stock
APTX
|
+$1.19M |
| 5 |
Viking Therapeutics
VKTX
|
+$1.09M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.24% |
| 2 | Technology | 0.34% |
| 3 | Consumer Staples | 0.21% |
| 4 | Financials | 0.17% |
| 5 | Consumer Discretionary | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$783B
| $108M | 23.81% |
4,330
+304
| +8% | +$82K |
|
2
PUT
iShares S&P 100 ETF
OEF
$19.8B
| $57.6M | 12.67% |
4,300
+300
| +8% | +$36.1K |
|
|
ESPR
3
PUT
DELISTED
Esperion Therapeutics
ESPR
| $38.9M | 8.57% |
8,467
+1,775
| +27% | +$85.5K |
|
|
4
PUT
Biogen
BIIB
$30.4B
| $38M | 8.36% |
1,263
-484
| -28% | -$154K |
|
|
5
Biogen
BIIB
$30.4B
| $37.9M | 8.34% |
125,975
+90,441
| +255% | +$28.9M |
|
6
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $23.1M | 5.08% |
3,219
+2,679
| +496% | +$220K |
|
7
CALL
Sarepta Therapeutics
SRPT
$1.63B
| $19.1M | 4.19% |
1,746
| – | – |
|
|
ODT
8
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
| $14.4M | 3.16% |
518,125
-5,528
| -1% | -$86.1K |
|
9
PUT
AstraZeneca
AZN
$267B
| $12.6M | 2.77% |
1,656
-147
| -8% | -$11.5K |
|
|
10
PUT
Sarepta Therapeutics
SRPT
$1.63B
| $9.43M | 2.07% |
864
-44
| -5% | -$5.5K |
|
|
ESPR
11
DELISTED
Esperion Therapeutics
ESPR
| $6.39M | 1.41% |
138,958
+38,589
| +38% | +$1.86M |
|
|
AMRN
12
CALL
Amarin Corp
AMRN
$293M
| $6.07M | 1.34% |
223
-269
| -55% | -$98.1K |
|
|
13
CALL
AstraZeneca
AZN
$267B
| $5.64M | 1.24% |
743
-1,172
| -61% | -$91.5K |
|
|
14
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2B
| $4.98M | 1.1% |
694
-1,185
| -63% | -$97.3K |
|
|
15
State Street SPDR S&P Biotech ETF
XBI
$10.1B
| $4.47M | 0.98% |
+62,266
| New | +$5.02M |
|
|
KYNB
16
PUT
Kyntra Bio
KYNB
$28.2M
| $4.24M | 0.93% |
37
-21
| -36% | -$23.6K |
|
|
AMRN
17
PUT
Amarin Corp
AMRN
$293M
| $3.74M | 0.82% |
137
+112
| +448% | +$40.8K |
|
|
ZGNX
18
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $3.61M | 0.79% |
991
-1,647
| -62% | -$67.4K |
|
|
BCLI
19
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
| $3.59M | 0.79% |
67,379
+6,915
| +11% | +$341K |
|
|
20
Xeris Biopharma Holdings
XERS
$1.42B
| $3.45M | 0.76% |
202,916
-284,022
| -58% | -$5.7M |
|
21
Oramed Pharmaceuticals
ORMP
$171M
| $2.8M | 0.62% |
933,050
+131,808
| +16% | +$546K |
|
|
22
PUT
Nektar Therapeutics
NKTR
$2.39B
| $2.69M | 0.59% |
54
-258
| -83% | -$156K |
|
|
23
Nektar Therapeutics
NKTR
$2.39B
| $2.59M | 0.57% |
5,261
-14,433
| -73% | -$8.71M |
|
|
ISEE
24
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $2.44M | 0.54% |
2,037,460
+418,640
| +26% | +$811K |
|
|
NTBL
25
DELISTED
Notable Labs, Ltd. Ordinary Shares
NTBL
| $2.3M | 0.51% |
67,806
+7,071
| +12% | +$312K |
|
Similar funds
CG
OC
ICCON
PCM
CAS
CM
MCMC
CTC
Sabby Management's Q4 2018 Portfolio in Review
As of Q4 2018, Sabby Management held 161 positions worth $455M, down 42% from $782M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Sabby Management withdrew a net $168M in Q4 2018, closing 40 positions and reducing 40 holdings. Its most notable exit was Amicus Therapeutics, an estimated $1.87M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 21% of assets, up from 15% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Sabby Management opened a new position in State Street SPDR S&P Biotech ETF worth $4.47M.
- Sabby Management's largest Q4 2018 buy was State Street SPDR S&P Biotech ETF: 62,266 shares worth $4.47M.
- Sabby Management added most to Biogen in Q4 2018, an estimated $28.9M increase.
- Sabby Management's biggest Q4 2018 reduction was Nektar Therapeutics, cutting an estimated $8.71M.
- Sabby Management fully exited Amicus Therapeutics in Q4 2018, selling an estimated $1.87M.
- Sabby Management's ten largest holdings make up 79% of its $455M portfolio in Q4 2018.
- Sabby Management opened 35 new positions and closed 40 in Q4 2018.
- Sabby Management's portfolio value fell 42% quarter-over-quarter to $455M.
Based on Sabby Management's 13F filing for Q4 2018, filed 14 Feb 2019.